InnoCan Pharma (INNO) investor relations material

Executive summary

• Focus on three pillars: human chronic pain management, animal health (veterinary pain), and wellness, each targeting large and growing markets.

• LPT/CBD, a monthly injectable, offers a non-opioid alternative for chronic pain, with robust preclinical efficacy, pharmacokinetic, and safety data supporting regulatory strategy.

• Wellness division continues to deliver high gross margins and resilient profitability despite US market headwinds, contributing to a strengthened balance sheet.

• Strategic partnerships and collaborations with leading academic, industry, and regulatory experts support regulatory and development progress.

• Progressing toward a significant milestone with a planned U.S. public offering.

Financial highlights

• Revenue for the nine months ended September 30, 2025, was $21.6 million, down 10% year-over-year.

• Gross profit was $19.5 million, a 10.5% decrease year-over-year.

• Gross margin remains high at 90.8%+, supported by supply chain optimization and cost savings.

• Operating loss was $0.333 million, a slight increase of 1.5% year-over-year.

• Over 75 products offered on Amazon in the USA, maintaining leading market share in key categories.

Outlook and guidance

• Plans to expand online presence, product portfolio, and digital channels in the wellness segment.

• Targeting first-in-human trials for LPT/CBD within 18 months, with parallel regulatory progress in human and animal health.

• Uplisting to a US public offering is in progress, delayed due to SEC strike but expected to resume soon.

• Strategic supply chain optimizations and tariff responses have positioned the company for improved performance as markets recover.

• Continued focus on regulatory milestones and U.S. public offering as next steps.